Talk Presenting Companies (Theatre A) track
Oncology: Bold Therapeutics Inc.
Mon, Nov 9, 2026 · 1:15–1:30 PM CET Koelnmesse
About this session
Bold Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel metallotherapeutic cancer therapies to address high unmet medical needs. The company's lead asset, BOLD-100, is a first-in-class ruthenium-based metallotherapeutic small molecule currently in Phase 2 clinical trials for advanced gastrointestinal cancers. BOLD-100 selectively targets GRP78, a key regulator of the Unfolded Protein Response leading to cellular apoptosis.
Speaker
-
EVP, Clinical Development · Bold Therapeutics Inc.
Speaker